| abstract |
The antibody comprises: strong complementarity determining regions (CDRs) and variable framework regions (FRs) of mAb TNV148 as described in Figure 4; weak chain regions of CDRs and FR variables of mAb TNV148 as described in Figure 5; and optionally further comprising the specific substitution from proline to serine within FR3 of mAb TNV148B as described in Figure 4. The patent contains 7 more claims. |